&lt;title&gt;Photodynamic therapy with aminolevulinic acid and meso-tetrahydroxyphenylchlorin: first initial clinical experience in Egypt&lt;/title&gt;

El-Far, Mohamed; Setate, A.; ElMaadawy, Merit

doi:10.1117/12.203455

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…examined 25 patients with primary lip SCC and showed a 96% complete response after 12 weeks (337). A brief report on the treatment of lip cancer was also published in 1995 (339) and followed by a case report indicating good cosmetic results (340). About this time, Scotia sought regulatory approval in the USA and Europe for palliative use of Temoporfin in head and neck malignancies.…”

Section: Clinical Experiencementioning

confidence: 99%

Temoporfin (Foscan^®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer^†,‡

Senge

Brandt

2011

Photochem & Photobiology

285

218

View full text Add to dashboard Cite

show abstract

Section: Clinical Experiencementioning

confidence: 99%

Temoporfin (Foscan^®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer^†,‡

Senge

Brandt

2011

Photochem & Photobiology

285

218

View full text Add to dashboard Cite

show abstract

“…20 El-Far et al made their first clinical experience with ALA-PDT in this period, but did not publish the results before 1995. 21 In 1989 Batlle's research group presented ex vivo studies following ALA incubation to determine the tumor localizing properties of porphyrins in tumor, liver, skin and brain. Tumor and liver accumulated the most PpIX.…”

Section: Further Development Of Ala-pdt From 1987-1992mentioning

confidence: 99%

ALA and its clinical impact, from bench to bedside

Krammer

Plaetzer

2008

Photochem Photobiol Sci

226

154

View full text Add to dashboard Cite

ALA-induced protoporphyrin IX (PpIX) is used for fluorescence diagnosis (ALA-FD) and for fluorescence-guided resection of both (pre)malignant and non-malignant diseases. ALA is also applied in photodynamic therapy (ALA-PDT) of superficial (pre)malignant lesions in dermatology, urology, neurosurgery, otorhinolaryngology, gynecology and gastroenterology. Today, ALA is approved as Levulan for actinic keratoses, the ALA-methyl ester Metvix for actinic keratoses and basal cell carcinoma, the ALA-hexyl ester Hexvix for the diagnosis of bladder cancer and Gliolan for malignant glioma. The use of ALA for PDT and FD was established around 25 years ago, with most of the fundamental knowledge gained at the "bench" and implemented at the "bedside" due to the diligence of a few researchers within the first 10 years of research. After 1993 ALA research was taken up by many groups. For patient treatment, several factors are relevant. Administered mainly in a topical or oral form, ALA penetrates tissue in a sub-optimal way, which is currently improved by special techniques and the use of ALA-esters. PpIX accumulation is elevated in many malignant tissues, several tissue abnormalities, and in mucosa. It is also found at elevated levels in macrophages, dendritic cells and activated lymphocytes. Following sufficient PpIX accumulation in the target cells, irradiation is carried out which may be accompanied by a burning sensation at the treatment site. Due to a saturation process of PpIX formation and rapid photobleaching during irradiation the risk of overtreatment is relatively low. Pharmacokinetical studies have demonstrated a low systemic photosensitivity and excretion of PpIX via natural routes.

show abstract

<title>Photodynamic therapy with aminolevulinic acid and meso-tetrahydroxyphenylchlorin: first initial clinical experience in Egypt</title>

Cited by 1 publication

References 0 publications

Temoporfin (Foscan^®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer^†,‡

Temoporfin (Foscan^®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer^†,‡

ALA and its clinical impact, from bench to bedside

Contact Info

Product

Resources

About

<title>Photodynamic therapy with aminolevulinic acid and meso-tetrahydroxyphenylchlorin: first initial clinical experience in Egypt</title>

Cited by 1 publication

References 0 publications

Temoporfin (Foscan®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer†,‡

Temoporfin (Foscan®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer†,‡

ALA and its clinical impact, from bench to bedside

Contact Info

Product

Resources

About

Temoporfin (Foscan^®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer^†,‡

Temoporfin (Foscan^®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer^†,‡